MITOXANTRONE (Novantrone) BAXTER 20 MG/10 ML
Offer type: salePublished: 02.01.2013
| Seller: |  nikolaevich vladimir |
| Phones: |  093-413-67-63 Show phone |
| Address: | Ukraine |
MITOXANTRONE BAXTER 20 MG/10 ML at a good price. with a good term. Delivery to any city. Phone 093-413-67-63
Dosage form
Concentrate for solution for infusion 10 mg/5 ml and
20 mg/10 ml
Composition
One vial contains
active substance - mitoxantrone hydrochloride 11.642 mg or 23.284 mg
excipients: sodium chloride, sodium acetate, kolotukhina ice, sodium sulfate anhydrous, acid chloromethane diluted with water for injection.
Description
Clear blue solution.
Pharmacotherapeutic group
Protivoopuholevymi. The anthracyclines.
Code ATC L01DB07
Pharmacological properties
Pharmacokinetics
After a single intravenous farmakokineticescoy can be characterized as a three-phase model.
Mitoxantrone is eliminated via renal and hepatobiliary. Only 20-32% of the administered dose was eliminated within the first five days after injection (urine 6-11% in feces - 13-25%). Detected in the urine 65% unchanged mitoxantrone, the remaining 35% consisted mainly of two insertnamehere and their connections to the glucuronide. Approximately two-thirds entered dozvidanja on the first day.
Excretion of mitoxantrone is slow, periodprivate is 12 days (ranges from 5-18 days), sohranyaetsya concentration of the drug in the tissues. Roughly the same period, the half-life of beliveable in patients receiving a single dose of mitoxantrone every 21 day patients receiving the drug for 5 consecutive days every 21 days.
Pharmacodynamics
Mitoxantrone - derived anthracyclines, which is associated with adorning. The mechanism of action is not fully elucidated. The drug obladaettakim effect on proliferating and neproliferirute human cells, suggesting that mitoxantrone has a specific effect on specific cell cycle.
Indications for use
cancer molochnokislaya, as monotherapy or inpart
combination chemotherapy (including advanced and
metastasectomy disease)
- recognisability
- nelimpoblastny acute leukemia vzroslyh (jalogny leukemia)
- storeclientregister multiple sclerosis or recurrent
multiple sclerosis
- hormonedisrupting prostate pain syndrome
Way of application and dose
Adults and elderly patients:
Breast cancer (including advanced metastasise form of the disease), non-Hodgkin's lymphoma.
Monotherapy: the recommended initial dose of mitoxantrone as monotherapy - 14 mg/m2 body surface area administered intravenously, when dealing with re-introduction of this dose are at intervals of 21 days. Wolnych with the suppression of bone marrow function (due to predshestvuyushchei or poor General condition) dose should bitsetting reduced to 12 mg/m2.
The dose and the interval between injections is determined depending on the degree of myelosupression.
Subsequent courses is typically used previous dosepro the condition that the level of white blood cells and platelets recovered to normalizati within 21 days after administration of the previous dose.
Dosage form
Concentrate for solution for infusion 10 mg/5 ml and
20 mg/10 ml
Composition
One vial contains
active substance - mitoxantrone hydrochloride 11.642 mg or 23.284 mg
excipients: sodium chloride, sodium acetate, kolotukhina ice, sodium sulfate anhydrous, acid chloromethane diluted with water for injection.
Description
Clear blue solution.
Pharmacotherapeutic group
Protivoopuholevymi. The anthracyclines.
Code ATC L01DB07
Pharmacological properties
Pharmacokinetics
After a single intravenous farmakokineticescoy can be characterized as a three-phase model.
Mitoxantrone is eliminated via renal and hepatobiliary. Only 20-32% of the administered dose was eliminated within the first five days after injection (urine 6-11% in feces - 13-25%). Detected in the urine 65% unchanged mitoxantrone, the remaining 35% consisted mainly of two insertnamehere and their connections to the glucuronide. Approximately two-thirds entered dozvidanja on the first day.
Excretion of mitoxantrone is slow, periodprivate is 12 days (ranges from 5-18 days), sohranyaetsya concentration of the drug in the tissues. Roughly the same period, the half-life of beliveable in patients receiving a single dose of mitoxantrone every 21 day patients receiving the drug for 5 consecutive days every 21 days.
Pharmacodynamics
Mitoxantrone - derived anthracyclines, which is associated with adorning. The mechanism of action is not fully elucidated. The drug obladaettakim effect on proliferating and neproliferirute human cells, suggesting that mitoxantrone has a specific effect on specific cell cycle.
Indications for use
cancer molochnokislaya, as monotherapy or inpart
combination chemotherapy (including advanced and
metastasectomy disease)
- recognisability
- nelimpoblastny acute leukemia vzroslyh (jalogny leukemia)
- storeclientregister multiple sclerosis or recurrent
multiple sclerosis
- hormonedisrupting prostate pain syndrome
Way of application and dose
Adults and elderly patients:
Breast cancer (including advanced metastasise form of the disease), non-Hodgkin's lymphoma.
Monotherapy: the recommended initial dose of mitoxantrone as monotherapy - 14 mg/m2 body surface area administered intravenously, when dealing with re-introduction of this dose are at intervals of 21 days. Wolnych with the suppression of bone marrow function (due to predshestvuyushchei or poor General condition) dose should bitsetting reduced to 12 mg/m2.
The dose and the interval between injections is determined depending on the degree of myelosupression.
Subsequent courses is typically used previous dosepro the condition that the level of white blood cells and platelets recovered to normalizati within 21 days after administration of the previous dose.
